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Safety experience with continued exposure to
ofatumumab in patients with relapsing forms
of multiple sclerosis for up to 3.5 years
Stephen L Hauser* , Anne H Cross , Kevin Winthrop, Heinz Wiendl ,
Jacqueline Nicholas, Sven G Meuth, Paul S Giacomini , Francesco Saccà ,
Linda Mancione, Ronald Zielman, Morten Bagger, Ayan Das Gupta, Dieter A Häring,
Valentine Jehl, Bernd C Kieseier, Ratnakar Pingili, Dee Stoneman, Wendy Su,
Roman Willi and Ludwig Kappos*

Abstract
Background: Ofatumumab is approved for the treatment of
relapsing multiple sclerosis (RMS). Ongoing safety reporting is crucial to understand its long-term benefit–risk profile.
Objective: Report the safety and tolerability of ofatumumab
in RMS after extended treatment up to 3.5 years.
Methods: Patients completing ASCLEPIOS I/II (phase 3),
APLIOS, or APOLITOS (phase 2) trials could enter ALITHIOS, a phase 3b, open-label, long-term safety study. We
analyzed cumulative data of continuous ofatumumab treatment and of patients newly switched from teriflunomide.
Results: The safety population had 1969 patients: 1292
continuously treated with ofatumumab (median timeat-risk 35.5 months, 3253 patient-years) and 677 newly
switched (median time-at-risk 18.3 months, 986 patientyears). A total of 1650 patients (83.8%) had ⩾1 adverse
events and 191 (9.7%) had ⩾1 serious adverse events. No
opportunistic infections or progressive multifocal leukoencephalopathy events were identified; the risk of malignancies was low. Mean serum immunoglobulin (Ig) G levels
remained stable. Mean IgM levels decreased but remained
above the lower limit of normal in most. Serious infection
incidence was low; decreased Ig levels were not associated
with serious infections.
Conclusion: In patients with up to 3.5 years’ exposure, ofatumumab was well tolerated, with no new safety risks identified.
These findings, with its established effectiveness, support a
favorable benefit–risk profile of ofatumumab in RMS.
Keywords: Ofatumumab, multiple sclerosis, antibodies,
monoclonal, relapsing multiple sclerosis, safety
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Introduction
Ofatumumab, the first fully human anti-CD20 monoclonal antibody (mAb),1 is a highly effective disease-modifying therapy (DMT)2 for the treatment of
relapsing multiple sclerosis (RMS).3,4 Fully human
mAbs are derived from human gene sequences
alone and are generally considered to have a low
immunogenic potential.5 Ofatumumab binds to two
distinct, noncontinuous regions on a unique conformational epitope of the CD20 receptor, including
the small and large extracellular loops,6 resulting in
a slower off-rate and greater binding affinity than
other anti-CD20 mAbs.1,6-9 Ofatumumab induces
B-cell lysis primarily through pronounced complement-dependent cytotoxicity.6,8,9 Owing to its high
potency, distinct mode of action,6,8,9 and subcutaneous delivery, ofatumumab is effective when administered at a low dose,10 and can be self-administered
after the initial dose has been given under medical
supervision.7
To produce rapid and sustained B-cell depletion
while minimizing B-cell repletion between doses,
ofatumumab is administered by subcutaneous
injection in 20 mg initial loading doses at weeks 0,
1, and 2, then followed by 20 mg monthly (q4w)
dosing starting at week 4. 10 The efficacy and
tolerability profile of ofatumumab in RMS was
investigated in the pivotal, randomized, doubleblind, phase 3 ASCLEPIOS I (NCT02792218) and
ASCLEPIOS II (NCT02792231) trials of up to
30 months’ duration7; in the 12 week, randomized,
phase 2 bioequivalence APLIOS (NCT03560739)
trial11; and in the 24 week, randomized, phase 2
APOLITOS trial, with an additional open-label
extension phase (NCT03249714).12 Ofatumumab is
currently approved in many countries including
European Union countries, the USA, Japan, the
United Kingdom, and Australia.
Following participation in the core parts of
ASCLEPIOS I/II, APLIOS, or the open-label extension part of APOLITOS, patients could enter
ALITHIOS (NCT03650114), which is an openlabel, phase 3b trial.13 The aims of ALITHIOS are to
assess the long-term safety of ofatumumab and to
examine its safety, tolerability, and effectiveness in a
population of patients with RMS.13,14 Here, we provide an update on the cumulative safety experience
with extended treatment of ofatumumab following
exposure for up to 3.5 years, with data from initiation of ofatumumab treatment in the core/extension
studies.

journals.sagepub.com/home/msj

Methods
Trial designs and patients
The ongoing, phase 3b, open-label, single-arm,
ALITHIOS umbrella extension trial of ofatumumab
20 mg subcutaneously q4w in RMS includes
patients who were randomized to ofatumumab in the
ASCLEPIOS I/II and APLIOS trials and who continued ofatumumab treatment in ALITHIOS. In addition, ALITHIOS includes patients randomized to
teriflunomide in ASCLEPIOS I/II who switched to
ofatumumab in ALITHIOS. ALITHIOS also includes
patients who were randomized to ofatumumab or placebo during the 24-week double-blind core part of
APOLITOS and who subsequently received ofatumumab during the APOLITOS open-label extension
part before entering ALITHIOS. The trial designs and
eligibility criteria of ASCLEPIOS I/II, APLIOS, and
APOLITOS are described elsewhere.7,11,12 The key
eligibility criteria are described in Supplementary
Appendix 1.
ALITHIOS started on 22 November 2018, and is
expected to complete in 2029.13 Patients will be
treated with ofatumumab in ALITHIOS for a maximum period of 5 years from joining this trial. The
present interim analysis provides up to 3.5 years of
cumulative safety data, from initiation of ofatumumab treatment in the core/extension studies to the
cut-off date of 29 January 2021. ALITHIOS trial
oversight information is described in Supplementary
Appendix 2.
Analysis populations
The safety analysis set consisted of all patients who
received at least one dose of ofatumumab in the
“overall safety population,” which comprised of
“continuous ofatumumab group” and “newly switched
ofatumumab group.” The continuous ofatumumab
group includes all patients randomized to ofatumumab
in ASCLEPIOS I/II (up to 30 months/120 weeks),
APLIOS (12 weeks), and APOLITOS (up to 72 weeks;
including patients who switched from placebo to ofatumumab in the APOLITOS open-label extension) and
who then continued in ALITHIOS; the group also
includes patients who completed/discontinued ofatumumab during one of the four trials and continued in
the safety follow-up of their respective trials, but did
not enter ALITHIOS. The safety follow-up period
lasted at least 9 months after the last dose administration, and all safety data from the first dose of ofatumumab until up to 100 days after the last dose were
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considered to be treatment-emergent (i.e. this period
was taken as a patient’s time at risk, as described in
Supplementary Appendix 3). The newly switched
ofatumumab group included patients who were randomized to teriflunomide in ASCLEPIOS I/II and
switched to ofatumumab on entering ALITHIOS.
Safety and laboratory assessments
Treatment-emergent adverse event (AE) data were
collected for the safety analysis set to determine the
number of patients who experienced an AE (including
grade and severity), with a particular focus on injection-related reactions (IRRs), infections, and malignancies. Safety data were summarized for all patients
in the continuous ofatumumab group, the newly
switched ofatumumab group, and the overall safety
population. Immunoglobulin G (IgG) and immunoglobulin M (IgM) levels were assessed at baseline,
week 4, week 12, and every 12 weeks thereafter in the
ASCEPLIOS studies; in the ALITHIOS study, data
were collected every 12 weeks up to week 48, and
every 24 weeks thereafter until the end of the study;
data were analyzed up to the cut-off date of 29 January
2021. The pregnancy outcomes in women inadvertently exposed to ofatumumab were also recorded up
to a cut-off date of 21 April 2021.
Statistical analyses
Occurrences of AEs were summarized as binary endpoints and presented as the percentage of patients
with at least one AE, AEs of grade 3 or 4 (combined)
severity, AEs leading to ofatumumab discontinuation,
serious AEs (SAEs), AEs occurring in at least 5%
of patients in the overall safety population, IRRs,
infections, malignancies, and pregnancies. Exposureadjusted incidence rates (EAIRs) per 100 patientyears and 95% confidence intervals (CIs) were
estimated for AEs, infections, serious infections, and
malignancies overall and by year (Supplementary
Appendices 4 and 5) and for the entire analysis
period using a Poisson model. Cumulative incidence
function (CIF) estimates were reported yearly to
adjust for competing risks (treatment discontinuation) and variable follow-up duration. The percentage of patients with IRRs associated with each of the
first five doses of ofatumumab was summarized for
the overall, continuously treated, and newly switched
groups.
Absolute serum IgG and IgM levels and change
(absolute and percentage) from baseline in IgG and
IgM levels were summarized over time for patients in
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the continuous ofatumumab group and in the newly
switched group. The percentages of patients who had
IgG or IgM levels below the lower limit of normal
(LLN) at least once post-baseline were also summarized (Supplementary Appendix 6). Absolute IgG
and IgM values, absolute change from baseline, and
percentage change from baseline in IgG and IgM levels were analyzed over time by subgroups of baseline
quartiles through week 168 in the continuous ofatumumab group. Serious infections occurring within
1 month prior to and until 1 month after low IgG/IgM
levels below the LLN were also assessed, as were
events of low IgG or IgM levels leading to treatment
interruption or discontinuations.
Results
Patient demographics
The overall safety population included 1969 patients,
of whom 1292 were in the continuous ofatumumab
group and 677 in the newly switched ofatumumab
group. Baseline patient demographics and disease
characteristics have been reported for the phase 3
ASCLEPIOS I/II trials7 and the phase 2 APLIOS and
APOLITOS trials.11,12 Baseline demographics for the
patient groups described in this analysis are summarized in Table 1. In total, 86.5% of patients (n = 1703)
who completed the ASCLEPIOS I/II, APLIOS, and
APOLITOS trials entered ALITHIOS (Figure 1).
Mean (standard deviation (SD)) age of patients in the
overall safety population was 38.7 (9.2) years, and
time since diagnosis was 6.4 (6.2) years.
Exposure to ofatumumab, expressed as time at risk, is
summarized in Table 2 and Supplementary Figure 1
for the overall safety population, continuous ofatumumab group, and newly switched ofatumumab
group. Median (range) time at risk and total patientyears at risk were 21.0 (0.0–51.8) months and 4239
patient-years in the overall safety population, 35.5
(0.0–51.8) months and 3253 patient-years in the
continuous ofatumumab group, and 18.3 (1.2–22.7)
months and 986 patient-years in the newly switched
ofatumumab group. Of the patients who entered
ALITHIOS, 1569 (92.1%) were still receiving ofatumumab treatment at the time of data cut-off.
Summary of overall AEs
In total, 1650 patients (83.8%) in the overall safety
population had at least one AE (continuous ofatumumab group, 1128 (87.3%); newly switched ofatumumab group, 522 (77.1%); Table 3). Most AEs were

journals.sagepub.com/home/msj

SL Hauser, AH Cross et al.
Table 1. Demographics and disease characteristics (safety analysis set).
Overall safety
population (N = 1969)
Age, years, mean (SD)
Female, no. (%)
Type of MS, no. (%)
Relapsing–remitting
Secondary progressive
Time since MS symptom
onset (years), mean (SD)
Time since MS diagnosis,
years, mean (SD)
EDSS score, mean (SD)

Continuous ofatumumab
group (n = 1292)

Newly switched
ofatumumab group (n = 677)

38.7 (9.2)
1345 (68.3)

38.0 (9.1)
889 (68.8)

40.1 (9.2)
456 (67.4)

1869 (94.9)
100 (5.1)
9.0 (7.3)

1223 (94.7)
69 (5.3)
8.5 (7.3)

646 (95.4)
31 (4.6)
9.9 (7.2)

6.4 (6.2)

5.9 (6.3)

7.3 (6.0)

2.9 (1.4)

2.9 (1.3)

2.8 (1.5)

MS: multiple sclerosis; EDSS: Expanded Disability Status Scale; SD: standard deviation. The data in the table are baseline values
corresponding to the last non-missing value before first administration of ofatumumab. For patients in the newly switched group,
baseline refers to the time prior to the first administration of ofatumumab in the ALITHIOS extension study. The EDSS scores
range from 0.0 to 10.0, with higher scores indicating worse disability.

Overall safety population
(N = 1969)
Continuously treated
ofatumumab (n = 1292)
Ofatumumab, 465
ASCLEPIOS I

Newly switched
ofatumumab (n = 677)

355 entered ALITHIOS
110 completed/discontinued
core study

Teriflunomide, 462

Ofatumumab, 481
ASCLEPIOS II

338 entered ALITHIOS
335 entered ALITHIOS
146 completed/discontinued
core study

Teriflunomide, 474

339 entered ALITHIOS

APLIOS

Ofatumumab, 284

279 entered ALITHIOS
5 completed/discontinued
core study

APOLITOS

Ofatumumab, 62

57 entered ALITHIOS
5 completed/discontinued
core study
ALITHIOS
(N = 1703)

Figure 1. Schematic summary of the patient flow in the analysis groups.
APOLITOS had two phases: a core phase of 0–24 weeks and an extension phase of 24–48 weeks.

mild to moderate in severity, with 11.0% of grade 3/4
AEs in the continuous group and 5.3% in the newly
switched group. In the continuous group, EAIRs
for total AEs were higher in the first year and
approximately constant through years 2, 3, and 4
(Supplementary Table 1). The nature and frequency
of the most common AEs were comparable with those
reported in ASCLEPIOS I/II,7 and no new safety signals were identified (Table 3).

journals.sagepub.com/home/msj

In the overall safety population, 191 patients (9.7%)
had at least one SAE (continuous ofatumumab group,
155 (12.0%); newly switched ofatumumab group, 36
(5.3%)); the corresponding EAIRs per 100 patientyears (95% CIs) in each group were 4.8 (4.1–5.5), 5.1
(4.4–6.0), and 3.7 (2.7–5.2), respectively (Table 3).
In the continuous group, EAIRs did not substantially
change year-by-year (Supplementary Table 1). The
most common SAEs in the overall safety population
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Table 2. Time at risk with ofatumumab (safety analysis set).

Time at risk, n (%)
<48 weeks (1 year)
48–96 weeks (1–2 years)
96–144 weeks (2–3 years)
144–192 weeks (3–4 years)
>192 weeks (4 years)
Time at risk, months, median
(range)
Patient-years

Overall safety
population (N = 1969)

Continuous ofatumumab
group (n = 1292)

Newly switched
ofatumumab group (n = 677)

131 (6.7)
910 (46.2)
265 (13.5)
525 (26.7)
138 (7.0)
21.0 (0.0–51.8)

108 (8.4)
257 (19.9)
264 (20.4)
525 (40.6)
138 (10.7)
35.5 (0.0–51.8)

23 (3.4)
653 (96.5)
1 (0.1)
0
0
18.3 (1.2–22.7)

4239

3253

986

Time at risk defined as the time from first dose of ofatumumab until 100 days after last dose.

were infections: appendicitis (n = 12; 0.6%), pneumonia (n = 9; 0.5%), COVID-19 pneumonia (n = 7;
0.4%), and urinary tract infection (n = 6; 0.3%).
Two deaths were reported, both in the continuous ofatumumab group, and neither were reported as related
to ofatumumab: one patient had COVID-19 pneumonia and another patient committed suicide.
AEs leading to ofatumumab discontinuation occurred
in 115 patients (5.8%) in the overall safety population, with 89 (6.9%) in the continuously treated group
and 26 (3.8%) in the newly switched group. The most
common AEs leading to discontinuation were reduced
IgM levels (n = 53, 46.1%) and other reduced immunoglobulin levels (n = 11, 9.6%); the study protocol
mandated ofatumumab treatment interruption based
on notably low immunoglobulin values.

IRRs
IRRs included systemic (occurring within 24 hours
after injection) and injection-site reactions. Systemic
IRRs occurred in 24.8% of the overall safety population, 26.0% of the continuous ofatumumab group, and
22.6% of the newly switched ofatumumab group
(Table 3). In the newly switched group, systemic IRRs
were mild-to-moderate (all grade 1/2), none were serious, and they rarely led to withdrawal of ofatumumab
(four patients discontinued treatment, two of which
were after the first injection). Of the 123 patients who
reported systemic IRRs after their first injection in the
newly switched group, 61% used premedication for the
first injection.. Systemic IRRs occurred mostly after
the first injection of ofatumumab, with 18.2% of
patients in the newly switched group experiencing
systemic IRRs after the first dose of ofatumumab.
This rate dropped markedly for subsequent injections
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(Figure 2 and Supplementary Table 2). These results
are consistent with those reported in ASCLEPIOS I/II.7
Injection-site reactions occurred in 11.5% of the overall safety population, 13.2% of the continuous ofatumumab group, and 8.3% of the newly switched
ofatumumab group (Table 3). In the newly switched
group, reactions were all mild-to-moderate (all grade
1/2) and non-serious, with one patient discontinuing
treatment owing to an injection-site reaction.

Infections
In the overall safety population, 1070 patients (54.3%)
had infections reported, an incidence similar to the
ofatumumab group in the ASCLEPIOS I/II studies
(51.6%).7 The EAIR per 100 patient-years (95% CIs)
for infections was 44.1 (41.5–46.8) (Table 3). The
most frequent infections were nasopharyngitis, upper
respiratory tract infection, urinary tract infection, and
COVID-19. There was no increase in the EAIR for
infections with extended exposure to ofatumumab;
the exception being upper respiratory tract infection,
which became more frequent by year 3 potentially
owing to the emergence of COVID-19 (Supplementary
Table 1). Overall incidence of infections remained
stable over time and did not increase (Supplementary
Figures 2 and 3). There were no opportunistic infections, hepatitis B reactivation, or progressive multifocal leukoencephalopathy events identified. Serious
infections were reported in 58 patients (2.9%) in the
overall safety population (Table 3), a rate consistent
with those observed in the ofatumumab groups of
ASCLEPIOS I (2.6%) and ASCLEPIOS II (2.5%).7
The EAIR per 100 patient-years (95% CIs) for serious infections was 1.4 (1.1–1.8; Table 3). The serious infections occurring in more than one patient in
the overall safety population were appendicitis,
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Table 3. Summary of AEs with ofatumumab (safety analysis set).
Patients with ⩾1 event, n
(%) (EAIR (95% CI))

Overall safety population
(N = 1969)

Patients with at least one AE
1650 (83.8) (148.7 (141.7–156.1))
Grade 3/4 AEs
178 (9.0)
Serious AEs
191 (9.7) (4.8 (4.1–5.5))
AEs leading to ofatumumab
115 (5.8)
discontinuation
AEs occurring in ⩾5% of the overall group
IRRs
  
Injection-related
489 (24.8) (15.0 (13.7–16.4))
systemic reaction
  Injection-site reaction
227 (11.5) (5.9 (5.2–6.8))
Infections
  All infections reported
1070 (54.3) (44.1 (41.5–46.8))
as AEs
  Nasopharyngitis
331 (16.8) (9.1 (8.2–10.2))
  Upper respiratory tract
203 (10.3) (5.2 (4.5–6.0))
infection
   Urinary tract infection
192 (9.8) (4.9 (4.2–5.6))
  COVID-19
114 (5.8) (2.7 (2.3–3.3))
Other AEs
  Headache
238 (12.1) (6.2 (5.5–7.1))
  IgM decreased
215 (10.9) (5.3 (4.7–6.1))
  Back pain
161 (8.2) (4.0 (3.5–4.7))
  Fatigue
135 (6.9) (3.4 (2.8–4.0))
  Arthralgia
133 (6.8) (3.3 (2.8–3.9))
  Diarrhea
108 (5.5) (2.7 (2.2–3.2))
Other AEs of interest occurring in <5% of the overall group
Malignancies occurring in more than one patienta
  All malignancies
11 (0.6) (0.3 (0.1–0.5))
   Basal cell carcinoma
4 (0.2) (0.1 (0.0–0.3))
  
Invasive breast
2 (0.1) (0.1 (0.0–0.2))
carcinoma
SAEs of interest
Serious infections occurring in more than one patient
   All serious infections
58 (2.9) (1.4 (1.1–1.8))
  Appendicitis
12 (0.6) (0.3 (0.2–0.5))
  Pneumonia
9 (0.5) (0.2 (0.1–0.4))
  COVID-19 pneumonia
7 (0.4) (0.2 (0.1–0.4))
   Urinary tract infection
6 (0.3) (0.1 (0.1–0.3))
  COVID-19
4 (0.2) (0.1 (0.0–0.3))
  Gastroenteritis
3 (0.2) (0.1 (0.0–0.2))
  Urosepsis
3 (0.2) (0.1 (0.0–0.2))
  Influenza
2 (0.1) (0.1 (0.0–0.2))
  Osteomyelitis
2 (0.1) (0.1 (0.0–0.2))

Continuous ofatumumab group
(n = 1292)

Newly switched ofatumumab
group (n = 677)

1128 (87.3) (153.4 (144.7–162.6))
142 (11.0)
155 (12.0) (5.1 (4.4–6.0))
89 (6.9)

522 (77.1) (139.6 (128.1–152.1))
36 (5.3)
36 (5.3) (3.7 (2.7–5.2))
26 (3.8)

336 (26.0) (13.5 (12.1–15.0))
171 (13.2) (5.9 (5.1–6.9))
761 (58.9) (43.8 (40.8–47.0))

153 (22.6) (19.8 (16.9–23.2))
56 (8.3) (6.1 (4.7–7.9))
309 (45.6) (44.8 (40.1–50.1))

257 (19.9) (9.4 (8.3–10.7))
148 (11.5) (5.0 (4.2–5.9))

74 (10.9) (8.2 (6.5–10.3))
55 (8.1) (5.9 (4.5–7.7))

156 (12.1) (5.2 (4.5–6.1))
70 (5.4) (2.2 (1.7–2.7))

36 (5.3) (3.8 (2.7–5.2))
44 (6.5) (4.5 (3.4–6.1))

197 (15.2) (6.9 (6.0–7.9))
153 (11.8) (4.9 (4.2–5.8))
135 (10.4) (4.5 (3.8–5.3))
112 (8.7) (3.7 (3.1–4.4))
102 (7.9) (3.3 (2.7–4.0))
94 (7.3) (3.0 (2.5–3.7))

41 (6.1) (4.3 (3.2–5.9))
62 (9.2) (6.6 (5.1–8.4))
26 (3.8) (2.7 (1.8–4.0))
23 (3.4) (2.4 (1.6–3.6))
31 (4.6) (3.2 (2.3–4.6))
14 (2.1) (1.4 (0.9–2.4))

8 (0.6) (0.3 (0.1–0.5))
3 (0.2) (0.1 (0.0–0.3))
1 (0.1) (0.0 (0.0–0.2))

3 (0.4) (0.3 (0.1–0.9))
1 (0.1) (0.1 (0.0–0.7))
1 (0.1) (0.1 (0.0–0.7))

48 (3.7) (1.5 (1.1–2.0))
11 (0.9) (0.3 (0.2–0.6))
7 (0.5) (0.2 (0.1–0.5))
6 (0.5) (0.2 (0.1–0.4))
4 (0.3) (0.1 (0.1–0.3))
3 (0.2) (0.1 (0.0–0.3))
3 (0.2) (0.1 (0.0–0.3))
3 (0.2) (0.1 (0.0–0.3))
2 (0.2) (0.1 (0.0–0.3))
1 (0.1) (0.0 (0.0–0.2))

10 (1.5) (1.0 (0.6–1.9))
1 (0.1) (0.1 (0.0–0.7))
2 (0.3) (0.2 (0.1–0.8))
1 (0.1) (0.1 (0.0–0.7))
2 (0.3) (0.2 (0.1–0.8))
1 (0.1) (0.1 (0.0–0.7))
0
0
0
1 (0.1) (0.1 (0.0–0.7))

AE: adverse event; CI: confidence interval; COVID-19: coronavirus disease 2019; EAIR: exposure-adjusted incidence rate per 100 patient-years; Ig:
immunoglobulin; IRR: injection-related reaction; SAE: serious AE. AEs leading to trial drug discontinuation are based on the entries on the AE electronic case
report form (eCRF) page with “action taken with trial treatment” selected as “Drug Withdrawn.”
aIncidence of malignancies includes malignancies that occurred during the core trials (n = 5): two cases of basal cell carcinoma from ASCLEPIOS II and one
case each of malignant melanoma in situ, recurrent non-Hodgkin’s lymphoma and invasive breast carcinoma from ASCLEPIOS I. The table also includes two
additional malignancy cases that have occurred beyond the treatment-emergent period.
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Grade 1

and causality in relation to treatment, as assessed by
the investigator are given in Supplementary Table 3.

Grade 2

20

Proportion of patients (%)

18
16
14
12
10
8
6
4
2
0

1

2

3

4

5

674

673

Injection number
No. of
patients

677

676

676

Figure 2. Injection-related systemic reactions by injection
number in the newly switched group (first five injections).

pneumonia, COVID-19 pneumonia, and urinary
tract infection. The EAIR (95% CI) for serious infections was 1.4 (1.1–1.8; Table 3) overall and did not
increase with long-term exposure to ofatumumab
(Supplementary Table 1).

COVID-19 infections
In the overall population, 139 patients (7.1%) had a
COVID-19-related AE, including 115 confirmed
(with positive laboratory confirmation as reported by
the investigator) and 24 suspected COVID-19 cases.
Of these confirmed and suspected COVID-19 cases,
investigators also reported an AE of COVID-19 pneumonia in 13 patients, and 10 patients were hospitalized due to COVID-19. The majority of patients with
a COVID-19-related AE recovered without sequelae
(n = 128; 92.1%). One patient was hospitalized and
died due to confirmed COVID-19 with COVID-19
pneumonia. No other patients discontinued treatment
owing to COVID-19.
Malignancies
In total, malignancy AEs were reported in 11 patients
(0.6%) in the overall safety population, with EAIRs
(95% CIs) of 0.3 (0.1–0.5) (Table 3). In the overall
population, malignancies reported by more than one
patient were basal cell carcinoma (n = 4) and invasive breast carcinoma (n = 2). EAIRs for malignancies did not increase over time (Supplementary
Figure 2). Details of malignancy type, time to onset,
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Pregnancy
Overall, there were four women in ASCLEPIOS I/II
and 10 women in ALITHIOS who were exposed to
ofatumumab during the first trimester of pregnancy.
Of these pregnancies, six resulted in early termination, one resulted in early intrauterine fetal demise at
approximately 8.5 weeks’ gestation, three resulted in
live birth, and four pregnancies were ongoing at data
cut-off. Among the three live births, all were full-term
deliveries with no birth defects, congenital anomalies,
hematological abnormalities, or serious infections in
the newborns reported up to the cut-off date of 21
April 2021.
Immunoglobulin levels
Mean serum levels of IgG remained stable throughout the entire treatment period in both the continuously treated and newly switched groups (Figure 3)
and, in the majority of patients, IgG levels remained
above the LLN (5.65 g/L). In the continuously
treated group, the percent change in IgG levels from
baseline was +1.1% at week 168. Mean serum levels of IgM decreased in both groups (Figure 3), and
in the majority of patients, IgM levels remained
above the LLN (0.40 g/L). In the continuously
treated group, the percent change in IgM levels
from baseline was −47% at week 168, with the
majority of the reduction occurring by week 48. In
the overall safety population, 30 patients (1.5%)
had IgG levels below LLN and 454 patients (23.1%)
had IgM levels below the LLN at least once postbaseline (Table 4).
In the continuously treated group, mean (SD) IgG and
IgM values were analyzed over time by baseline quartile of IgG and IgM levels, respectively, from baseline
to week 168 (Figure 4). Mean IgG levels were relatively stable in each quartile from baseline to week
168. Mean IgM levels in each baseline quartile
decreased over time but stayed above the LLN for all
quartiles from baseline to week 168. Overall, 179
patients (9.1%) interrupted treatment per protocol
because of notably low IgM levels (>10% below
the LLN) that were reported as AEs, with 65
patients (3.3%) permanently discontinuing treatment (Supplementary Table 4). Treatment interruptions and permanent discontinuations due to low IgG
levels occurred in two patients (0.1%) and four patients
(0.2%), respectively (Supplementary Table 4).
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1
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0.8
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0.6
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0.2
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Time from baseline (weeks)
No. of patients at visit
Continuously treated
ofatumumab
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Figure 3. Serum immunoglobulin levels from baseline up to week 168 in the continuous and newly switched groups
(safety analysis set): (a) IgG levels and (b) IgM levels.
R1: The first patient with first treatment-emergent assessment in ofatumumab period after switching to ofatumumab (72 weeks); R2:
The last patient with last treatment-emergent assessment in teriflunomide period before switching to ofatumumab (120 weeks); BL:
baseline; Ig: immunoglobin; LLN: lower limit of normal; SE: standard error.
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Table 4. Low serum levels (below the LLN at least once) for IgG and IgM (safety analysis set).
Overall safety population
(N = 1969)

Continuous ofatumumab
group (n = 1292)

Newly switched
ofatumumab group
(n = 677)

Low IgG, n (%)
<5.65 g/L
Low IgM, n (%)

30 (1.5)

22 (1.7)

8 (1.2)

<0.40 g/L

454 (23.1)

324 (25.1)

130 (19.2)

LLN for IgG = 5.65 g/L; LLN for IgM = 0.40 g/L. Ig: immunoglobulin; LLN: lower limit of normal.
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In general, the number of serious infections was low
in ALITHIOS. In the overall population, the proportion (number) of patients with serious infection SAEs
within 1 month before or after any decline in IgG was
3.3% (1/30) in patients who had IgG levels below the
LLN (5.65 g/L) at any time post-baseline and 2.8%
(55/1936) in those whose levels remained equal to or
above the LLN. Corresponding values for IgM were
0.7% (3/454) in patients with IgM levels below the
LLN (0.40 g/L) at any time post-baseline and 2.9%
(44/1512) in patients whose IgM levels remained
equal to or above the LLN (Table 5). One patient
whose IgG levels were below the LLN had a serious
infection SAE (pneumonia). Three patients whose
IgM levels were below the LLN at any time had a
serious infection SAE (herpes zoster; upper respiratory tract infection; urinary tract infection). Further
information about these patients is provided in
Supplementary Table 5.

rate after the first placebo injections in the teriflunomide arm in ASCLEPIOS (15.0%).7 The low incidence of systemic IRRs with ofatumumab after the
initial dose is possibly attributable to a limited recovery of circulating B-cells between doses with the
approved dosing regimen.15 All of the IRRs (site
and systemic) in the newly switched group were
non-serious and mild-to-moderate, and none required
treatment discontinuation. When compared to other
anti-CD20 therapies, ofatumumab was associated
with fewer and less severe systemic IRRs.7,16,17 The
rate of serious infections did not increase over time
and was also similar to that observed in ASCLEPIOS.
Overall, there were no opportunistic infections and
no hepatitis B reactivation or progressive multifocal
leukoencephalopathy events. In addition, B-cell
repletion after treatment cessation is faster with ofatumumab (approximately 24 weeks after cessation)18
than with other anti-CD20 therapies (72 weeks after
cessation).19

Discussion
This analysis provides a robust picture of extended
safety data for ofatumumab, with a larger population
size (approximately 2000 patients with RMS)
exposed for a longer period (up to 3.5 years and
4238.5 patient-years) than those reported in previous
studies.7,11,12 The proportions of patients with AEs,
SAEs, grade 3/4 AEs, and AEs leading to discontinuation were consistent with those observed in the core
ASCLEPIOS I/II trials,7,11,12 and EAIRs for AEs and
SAEs did not increase over time. The risks of serious
infections or malignancies, few of which were previously reported,7 did not increase with additional ofatumumab exposure.

Low serum immunoglobulin levels, which can occur
with anti-CD20 therapies,20-24 have been linked with
an apparent risk of infection.25-27 In patients treated
with ofatumumab, including the group that received
continuous treatment of up to 3.5 years, mean IgG
levels remained similar to baseline values. Mean IgM
levels decreased over time; however, in the majority
of patients, IgM levels remained above the LLN
throughout. The overall incidence of serious infections was low, and no association was observed
between decreased immunoglobulin levels and the
risk of serious infections. These results were consistent with the 96-week phase 3 ASCLEPIOS I/II trial
data.6

The incidence of systemic IRRs after first injection in
patients who newly switched to ofatumumab in
ALITHIOS (18.2%) was similar to that observed in
those who initiated ofatumumab in the ASCLEPIOS
trials (20.2%) and not substantially different from the

The observed incidence of COVID-19 infections and
related outcomes in ofatumumab-treated patients
show no evidence of an increase in the incidence or
severe outcomes of COVID-19 infections compared
to the general population28 and that the majority of
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Figure 4. Serum immunoglobulin levels up to week 168 in the continuous ofatumumab group, by baseline quartile value
(safety analysis set): (a) IgG levels and (b) IgM levels.
IgG quartiles (Q): Q1, <8.57 g/L; Q2, ⩾8.57 and <10.07 g/L; Q3, ⩾10.07 and <11.51 g/L; Q4, ⩾11.51 g/L. IgM quartiles (Q): Q1,
<0.81 g/L; Q2, ⩾0.81 and <1.14 g/L; Q3, ⩾1.14 and <1.57 g/L; Q4, ⩾1.57 g/L. BL, baseline; Ig: immunoglobin; SE: standard error.

COVID-19 infections in ofatumumab-treated patients
are self-limited. Although reassuring, these observations are still preliminary and it would be premature
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to draw firm conclusions at this time about potential
effects of ofatumumab treatment on the incidence or
severity of COVID-19 infection.
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Table 5. Association of serious infections with IgG/IgM decrease in ofatumumab-treated patients (overall group).

Patients with at least 1
serious infection
Herpes zoster
Upper respiratory tract
infection
Urinary tract infection
Pneumonia

Overall

IgM

IgG

N = 1969

<LLNa (n = 454)

⩾LLN (n = 1512)

<LLN (n = 30)

⩾LLN (n = 1936)

n (%)

EAIR

n (%)

EAIR

n (%)

EAIR

n (%)

EAIR

n (%)

EAIR

58 (2.9)

1.39

3 (0.7)

0.80

44 (2.9)

1.38

1 (3.3)

7.02

55 (2.8)

1.34

1 (0.1)
1 (0.1)

0.02
0.02

1 (0.2)
1 (0.2)

0.27
0.27

0
0

0
0

0
0

0
0

1 (0.1)
1 (0.1)

0.02
0.02

6 (0.3)
9 (0.5)

0.14
0.21

1 (0.2)
0

0.27
0

3 (0.2)
8 (0.5)

0.09
0.25

0
1 (3.3)

0
7.02

6 (0.3)
8 (0.4)

0.14
0.19

EAIR: exposure-adjusted incidence rate; Ig: immunoglobulin; LLN: lower limit of normal. For all pooled analyses, a fixed value of LLN (using ALITHIOS
study reference) was used. LLN for IgG: 5.65 g/L; IgM: 0.4 g/L.
aPatients with ⩾1 serious infection within 1 month prior to and until 1 month (defined as episodes) after any series of drop in IgG/IgM levels < LLN. Time at
risk for this group of patients is defined as the sum of duration of such episodes until the onset of serious infection.

The mean age of patients in this analysis was
38.7 years at baseline, and people living with MS up
to the age of 55 at baseline were included in this
study. It would be important to understand the benefit and safety profile of ofatumumab treatment in
older patients or in those with greater degrees of disability, who may be more vulnerable to certain AEs.
In the small cohort analysis of 14 pregnant women
exposed to ofatumumab, there were no birth defects,
congenital anomalies, or serious infections reported
to date. Future registry studies will provide additional
data on maternal exposure to ofatumumab.
Compared with other injectable therapies for MS,
monthly ofatumumab subcutaneous injections are
less burdensome for patients11 than the more frequent injections required with interferon-beta or
glatiramer acetate. Ofatumumab was rarely associated with flu-like symptoms, which occur frequently
with interferon-beta. These factors provide a plausible explanation for the high adherence observed
with ofatumumab treatment (only 2/1882 (0.2%) of
patients discontinued from the treatment epoch
owing to non-compliance).29 Another advantage of
ofatumumab’s subcutaneous route of administration
over DMTs that require intravenous infusion is the
convenience of self-administration at home. Without
the need for clinic time and infusion costs, there are
also potential cost-effectiveness advantages associated with ofatumumab.30
One limitation of these new analyses is the lack of
a comparator cohort. However, this is a common limitation of long-term studies and does not undermine
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the utility of data reported specifically for long-term
safety follow-up.
The safety profile with continued exposure and additional patients who switched to ofatumumab did
not change from that reported during the phase 3
ASCLEPIOS I/II trials,7 and no new safety signals
were detected. The ALITHIOS trial is expected to
continue until 2029, and post-marketing surveillance
is ongoing to identify any new safety signals.
In conclusion, the cumulative safety data suggest
that extended treatment with ofatumumab up to
3.5 years is well tolerated in patients with RMS, and,
in conjunction with its established effectiveness, are
supportive of a favorable benefit–risk profile of ofatumumab for patients with RMS, including patients
with early MS.
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